文献速递认知障碍与痴呆

仑卡奈单抗治疗早期阿尔茨海默病的成本效益分析

Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease.
PubMed 文献 · Neurology · 2024-03-14

本研究采用混合决策树-Markov队列模型,比较7种检测-治疗-靶向策略对早期阿尔茨海默病患者的成本效益。结果显示,与单独标准治疗相比,无论采用何种检测方法,靶向或非靶向仑卡奈单抗治疗均不具备成本效益;若仑卡奈单抗年定价低于5100美元,脑脊液检测后靶向治疗则可能具有成本效益。

要点

  • 从成本效益角度,单独标准治疗是7种策略中的最优策略。
  • 与单独标准治疗相比,靶向或非靶向仑卡奈单抗治疗均不具备成本效益。
  • 若仑卡奈单抗年定价低于5100美元,脑脊液检测后靶向治疗可能具有成本效益。

核心结论

  • 对于阿尔茨海默病所致轻度认知障碍或轻度痴呆患者,与单独标准治疗相比,靶向或非靶向仑卡奈单抗治疗均不具备成本效益。
  • 若仑卡奈单抗年定价低于5100美元,在某些情况下可能具有成本效益。

研究设计与样本

  • 构建混合决策树-Markov队列模型,包含轻度认知障碍、轻度痴呆、中度痴呆、重度痴呆和死亡5种状态。
  • 比较7种由检测方法(PET、脑脊液或血浆检测)、治疗选择(单独标准治疗或仑卡奈单抗联合标准治疗)和靶向策略(靶向APOE ε4非携带者、杂合子或不靶向)组合定义的检测-治疗-靶向策略。
  • 效果以质量调整生命年衡量,成本从第三方和社会视角以2022年美元估计,时间跨度為终身。

主要发现

  • 在7种检测-治疗-靶向策略中,单独标准治疗从成本效益角度为最优策略。
  • 与单独标准治疗相比,无论采用何种检测方法诊断早期阿尔茨海默病,靶向仑卡奈单抗治疗或不受APOE ε4基因型限制的治疗均不具备成本效益。
  • 若仑卡奈单抗年定价低于5100美元,脑脊液检测后靶向治疗将具有成本效益。
  • 上述结果对诊断检测准确性、仑卡奈单抗停药率和不良事件率均稳健。

临床怎么用

  • 对于阿尔茨海默病所致轻度认知障碍或轻度痴呆患者,与单独标准治疗相比,靶向或非靶向仑卡奈单抗治疗均不具备成本效益。
  • 若仑卡奈单抗年定价低于5100美元,脑脊液检测后靶向治疗在某些情况下可能具有成本效益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Little is known regarding the cost-effectiveness of lecanemab (Leqembi), a monoclonal antibody approved by the US Food and Drug Administration in January 2023 for the treatment of mild cognitive impairment (MCI) or mild dementia due to Alzheimer disease (AD). This study aims to quantify the cost-effectiveness of lecanemab and how it varies based on the accuracy of AD testing and individuals' APOE ε4 status. METHODS: Seven alternative test-treat-target strategies defined by combinations of testing approaches (PET, CSF, or plasma assay), treatment choices (standard of care [SoC] alone or lecanemab in addition to SoC), and targeting strategies (targeting APOE ε4 noncarriers or heterozygous patients or not) were compared. A hybrid decision tree-Markov cohort model was constructed with 5 states: (1) MCI (Clinical Dementia Rating-Sum of Boxes [CDR-SB] 0-4.5); (2) mild dementia (CDR-SB 4.6-9.5); (3) moderate dementia (CDR-SB 9.6-16); (4) severe dementia (CDR-SB >16); and (5) death. Effectiveness was measured by quality-adjusted life years and costs from third-party and societal perspectives were estimated in 2022 US dollars over a lifetime horizon. RESULTS: Among the 7 test-treat-target strategies, SoC alone was the optimal strategy from a cost-effectiveness perspective. Neither targeted lecanemab treatment nor treatment unrestricted by APOE ε4 genotype was cost-effective vs SoC alone, regardless of the test used to diagnose patients with early-stage AD. However, CSF assay followed by targeted treatment would become cost-effective if lecanemab is priced below $5,100 per year. These results were robust to the accuracy of diagnostic testing and rates of lecanemab discontinuation and adverse events. DISCUSSION: Neither targeted lecanemab treatment nor treatment unrestricted by APOE ε4 genotype is cost-effective vs SoC alone for patients with MCI or mild dementia due to AD. Lecanemab would be cost-effective in some settings if priced below $5,100 per year.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Nguyen HV, Mital S, Knopman DS, et al. Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease. Neurology. 2024. PMID: 38484190. doi:10.1212/WNL.0000000000209218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。